

# PRESS RELEASE

## IDOGEN AB



Corp. Reg. No. 556756-8521  
Date: September 24, 2021

### Board of Directors and management of Idogen AB to exercise all of their TO 4 warrants and acquire new shares

Idogen's Board of Directors and management (CEO, CSO and CFO) who hold subscription warrants (TO 4) will all redeem their warrants (TO 4) in full to purchase new shares in the company.

The TO 4 subscription warrants are part of the rights issue completed by the company in November 2020 that provides entitlement to acquire shares in Idogen AB for 70% of the volume-weighted price during the period September 6 – 21, 2021. The subscription price for one new share has now been determined at SEK 2.06 per share.

The final date for trading with TO 4 is Friday, October 1, though the final date for subscription is October 5, according to schedules from various administrators. The outcome will be announced in a press release on October 8. The planned date for the conversion to shares is October 20.

For more information, please visit Idogen's [website](#)

**Lund, September 24, 2021**  
Idogen AB (publ)

**For further information, please contact:**

Anders Karlsson, CEO, Idogen AB  
Phone: +46 (0) 709 18 00 10  
Email: [anders.karlsson@idogen.com](mailto:anders.karlsson@idogen.com)

*The information was submitted for publication, through the agency of the contact person set out above, for publication on September 24, 2021 at 08:45 CEST.*

**Certified Adviser**

The company's Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm; phone: +46 (0)8-463 80 00, email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

*Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third program, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.*